General Discussions

Combinations May Combat PARP Resistance

By Leslie M. Randall, MD, MAS
PUBLISHED WEDNESDAY, DECEMBER 31, 1969


The implementation of PARP inhibitors is one of the most exciting additions to the treatment of gynecologic cancer, said Leslie M. Randall, MD, MAS, associate professor in the Division of Gynecologic Oncology at the University of California in Irvine.

However, many patients become resistant to the drugs and progress. Combinations, such as a PARP inhibitor plus an immunotherapy agent or PI3K inhibitor, are now being explored to overcome this resistance and lead to better outcomes.
Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.